Group 1 - Bernstein Private Wealth Management is expanding its ultrahigh-net-worth (UHNW) services through inorganic growth strategies, including targeted recruiting and selective acquisitions of registered investment advisors (RIAs) [2][3] - The firm has appointed three new leaders: Craig Storch as Senior Managing Director for Growth Strategies, Neel Ray as Senior National Director, and Marshall Butler as Head of Marketing, all reporting to Aaron Bates [2][3][5] - Bernstein's UHNW segment is experiencing notable momentum, and the firm aims to leverage its global asset management resources to enhance advisor practices and client outcomes [3][4] Group 2 - The new hires and acquisitions will be based on cultural fit and fiduciary mindset, aligning with Bernstein's long-standing commitment to organic talent development [3][4] - Bernstein continues to introduce tailored solutions for UHNW clients, including family offices, and has opened a new office in Hudson Yards, New York City [6] - As of May 31, 2025, AllianceBernstein manages $803 billion in assets, positioning Bernstein among the largest investment managers globally [7]

Core Viewpoint - AB Science S.A. successfully completed a private placement raising EUR 1.925 million to finance ongoing activities, particularly the clinical development of the AB8939 program [1][3]. Use of Proceeds - The net proceeds from the private placement will be utilized to support the clinical development of the AB8939 program and strengthen the company's cash position to meet financing needs for 2025 and beyond [3]. Private Placement Details - The private placement involved the issuance of 1,645,302 new ordinary shares, each with an attached share warrant (BSA), without preferential subscription rights [4][5]. - The issue price of one ABSA is EUR 1.17, reflecting a 24.36% discount to the volume-weighted average price (VWAP) of AB Science shares over the three trading days prior to the pricing [6][7]. Shareholder Impact - Post-placement, the new shares will represent approximately 2.47% of the company's share capital on a non-diluted basis before the placement and 2.41% after [5]. - Existing shareholders who do not participate in the private placement will experience a dilution of their shareholding [12][22]. Trading and Admission - The new shares are expected to be admitted to trading on Euronext Paris on July 10, 2025, and will be assimilated to existing shares [13]. Lock-up Commitments - The company has agreed to a 45-day lock-up period for the investors and a 90-day lock-up for its directors and officers following the settlement and delivery of the private placement [17].

Core Viewpoint - The FDA and EMA have authorized a confirmatory Phase 3 trial for masitinib in metastatic castrate-resistant prostate cancer (mCRPC), utilizing a biomarker-driven patient selection approach to target those most likely to benefit from the treatment [1][2]. Study Design - Study AB22007 is a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial designed to confirm the efficacy and safety of masitinib in combination with docetaxel for mCRPC patients [3]. - The trial will enroll 600 patients, with a primary endpoint of radiographic progression-free survival (rPFS) and overall survival as the first secondary endpoint [4]. Medical Need - Masitinib is positioned to address a high unmet medical need in mCRPC patients who have relapsed after hormone treatments, as there are currently no registered drugs for use in combination with docetaxel in this patient population [5][6]. - Metastatic prostate cancer has a 5-year survival rate of approximately 30%, highlighting the critical need for effective treatments [7]. Patient Population - The estimated population of mCRPC patients eligible for chemotherapy is around 75,000 in the EU and 50,000 in the USA [8]. - The biomarker alkaline phosphatase (ALP) has been validated to predict the response to masitinib in mCRPC patients, indicating a potential new first-line treatment option [8]. Efficacy Results - The combination of masitinib and docetaxel showed a significant progression-free survival (PFS) benefit, with a hazard ratio of 0.79, indicating a 21% reduction in the risk of progression compared to control [10]. - A greater treatment effect was observed in patients with lower baseline ALP levels, with a 47% reduced risk of progression in those with ALP ≤ 100 IU/L [11]. Safety Profile - The safety profile of masitinib in combination with docetaxel was acceptable, with no new safety signals observed, marking a successful example of a Phase 3 trial that improved PFS [13]. Patent Protection - AB Science has filed a patent application for methods of treating mCRPC with masitinib, which has been granted by the European Patent Office, providing protection until 2042 for the treatment of mCRPC in patients with low metastatic involvement [14][15].

Core Viewpoint - AllianceBernstein L.P. and AllianceBernstein Holding L.P. will release their Second Quarter 2025 financial and operating results on July 24, 2025, before market opening [1] Group 1: Financial Results Announcement - The financial results will be discussed in a teleconference starting at 9:00 am (CT) on July 24, 2025, hosted by key executives including the President and CEO, CFO, and Head of Global Client Group and Private Wealth [1] - The presentation for the conference call will be available on the Investor Relations website shortly after the results are released [2] - A replay of the webcast will be accessible approximately one hour after the conference call concludes on the same day [2] Group 2: Company Overview - AllianceBernstein is recognized as a leading global investment management firm, providing diversified investment services to institutional investors, individuals, and private wealth clients across major world markets [3] - As of March 31, 2025, AllianceBernstein Holding owned approximately 37.5% of AllianceBernstein, while Equitable Holdings, Inc. owned about 61.9% economic interest in the firm [4]

Core Viewpoint - AB Science has reached an agreement in principle with its financial creditors to postpone the repayment of its bank debt by 24 months, contingent upon the postponement of a loan repayment with the EIB by at least 12 months [2][7]. Group 1: Loan Repayment Terms - The total amount of bank debt to be postponed is approximately 3.7 million euros, with the agreement conditional on a 12-month delay for a 12 million euro loan from the EIB, originally due in January and December 2028 [2][4]. - The restructuring terms include state-guaranteed loans (PGE) with a balance of 3.5 million euros [3]. - A freeze on principal repayments is set from January 1, 2025, to December 31, 2026, with amortization resuming on January 1, 2027 [8]. Group 2: Financial Strategy - Savings from the postponed repayments will be invested in research and development [7]. - The EIB loan is structured in two tranches of 6 million euros each, with specific maturity dates in 2028 [4]. - An innovation loan with a balance of 0.2 million euros will also have a freeze on principal repayments from January 1, 2025, to September 30, 2025, with amortization resuming on October 1, 2025 [8]. Group 3: Company Overview - AB Science, founded in 2001, specializes in the research, development, and commercialization of protein kinase inhibitors (PKIs) targeting diseases with high unmet medical needs [5][6]. - The company's lead compound, masitinib, is already registered for veterinary use and is being developed for human medicine across various disease areas [6].

Core Viewpoint - New peer-reviewed data supports masitinib's potential as a treatment for sporadic Alzheimer's disease through cognitive enhancement and neuroprotection [1][5][6] Group 1: Clinical Evidence - A new study from independent researchers indicates that masitinib improves cognitive functions in a mouse model of sporadic Alzheimer's disease, showing enhancements in memory, learning, and anxiety-like behaviors [3][4] - The study demonstrated that masitinib reduced toxic brain proteins, alleviated synaptic dysfunction, and suppressed microglial activation, which is linked to inflammation in Alzheimer's disease [4][5] - Results from a phase 2B/3 study (AB09004) showed that masitinib treatment significantly reduced cognitive impairment in patients with mild Alzheimer's disease, with a notable improvement in the mild impairment subgroup [8][9] Group 2: Regulatory and Development Status - The FDA and key EU countries have authorized a phase 3 clinical study (AB21004) to evaluate masitinib as a disease-modifying therapy for Alzheimer's disease [10][11] - The phase 3 study aims to confirm previous findings from the phase 2B/3 study regarding masitinib's efficacy in slowing cognitive deterioration and improving daily living activities [12] Group 3: Intellectual Property - AB Science has filed a patent application for masitinib's use in treating Alzheimer's disease, which, if granted, will provide protection until 2041 [13]

Company Overview - AllianceBernstein Holding L.P. and AllianceBernstein L.P. are leading global investment management firms, with a focus on diversified investment services for institutional investors, individuals, and private wealth clients [4] - As of May 2025, AllianceBernstein had $803 billion in assets under management, showcasing its significant presence in the investment management industry [4] Product Launch - The company announced the launch of the AB Emerging Markets Opportunities ETF (EMOP), an actively managed ETF listed on the New York Stock Exchange, aimed at providing investors with access to emerging markets [1][2] - The ETF is designed to meet the growing demand for non-US equity exposures, particularly in emerging markets, reflecting the company's commitment to evolving client needs [2] Investment Strategy - EMOP aims for long-term capital growth by investing at least 80% of its net assets in equity securities of issuers economically tied to emerging markets [2] - The fund focuses on equity securities that offer compelling profitability prospects, reasonable valuations, and favorable fundamental and quantitative trends, leveraging the company's extensive experience in emerging markets [2][3] Expertise and Support - The dedicated Emerging Markets Equity team at AllianceBernstein combines fundamental research with quantitative tools, enhancing the fund's investment strategy [3] - The ETF is positioned as a strong option for model-builders and long-term investors seeking active management for their emerging market allocations [3]

Core Points - AB Science has announced the issuance of a Canadian patent for AB8939, which protects its composition and use in treating acute myeloid leukemia (AML) until 2036 [1] - The patent completes the intellectual property coverage for AB8939 across all key geographic areas, including Europe, USA, China, Japan, South Korea, India, Israel, Latin America, and Australia [2] - AB8939 is a novel microtubule destabilizer currently in early phase clinical trials for AML, with the first phase focusing on determining the maximum tolerated dose [3] - The drug is also eligible for regulatory data protection in Canada, preventing generic competition for 8 years post-approval, and has received orphan drug designation from EMA and FDA, providing additional market exclusivity [4] - A separate patent application has been filed to protect AB8939 for treating AML with specific chromosomal abnormalities, potentially extending protection until 2044 [5] - AB8939 targets cancer cells by destabilizing microtubules and inhibiting enzymes essential for cancer stem cell survival [6] - AB Science specializes in developing protein kinase inhibitors for diseases with high unmet medical needs and has a portfolio of molecules including masitinib [7][8]

Core Insights - AllianceBernstein L.P. and AllianceBernstein Holding L.P. reported a preliminary increase in assets under management (AUM) to $803 billion in May 2025, up from $781 billion at the end of April, representing a 2.8% month-over-month growth driven by market appreciation, despite net outflows [1][4] Summary by Category Assets Under Management - AUM increased to $803 billion as of May 31, 2025, from $781 billion at April 30, 2025 [1][4] - The increase was attributed to market appreciation, which was partially offset by net outflows [1] Breakdown by Channel - Private wealth saw slight inflows, while institutional and retail channels experienced outflows [1] - The total AUM breakdown includes: - Total Equity: $332 billion, up from $315 billion - Total Fixed Income: $296 billion, up from $295 billion - Alternatives/Multi-Asset: $175 billion, up from $171 billion [3][4] Detailed AUM Composition - Actively Managed Equity: $263 billion - Passive Equity: $69 billion - Total Fixed Income: $296 billion, with Taxable Fixed Income at $207 billion and Tax-Exempt at $79 billion - Alternatives/Multi-Asset: $175 billion [3][4]

PRESS RELEASE AB SCIENCE ANNOUNCES EMA APPROVAL OF MASIVET® SHELF-LIFE EXTENSION TO 4 YEARS Paris, June 9, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the European Medicine Agency (EMA) has approved the extension of the shelf-life of its veterinary medicine MASIVET® from 36 months to 48 months. This shelf-life extension applies to the 50mg tablet strength of MASIVET® currently available in the EU. MASIVET® is currently approved for the treatment of non-resectable dog mast ...